Journal for ImmunoTherapy of Cancer (Nov 2023)

1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors

Matteo Zago,
Yun Peng,
Meghan M Verstraete,
Maya Poffenberger,
Veronica Luu,
Brenda Ma,
Nichole Escalante,
Janessa Li,
Diego Perez Escanda,
Siran Cao,
Edward Meier,
Sifa Arrafi,
Anna Von Rossum,
Genevieve Desjardins,
Nina Weisser,
Thomas Spreter von Kreudenstein

Affiliations

Matteo Zago: Zymeworks BC Inc., Vancouver, BC, Canada
Yun Peng: Zymeworks BC Inc., Vancouver, BC, Canada
Meghan M Verstraete: Zymeworks BC Inc., Vancouver, BC, Canada
Maya Poffenberger: Zymeworks BC Inc., Vancouver, BC, Canada
Veronica Luu: Zymeworks BC Inc., Vancouver, BC, Canada
Brenda Ma: Zymeworks BC Inc., Vancouver, BC, Canada
Nichole Escalante: Zymeworks BC Inc., Vancouver, BC, Canada
Janessa Li: Zymeworks BC Inc., Vancouver, BC, Canada
Diego Perez Escanda: Zymeworks BC Inc., Vancouver, BC, Canada
Siran Cao: Zymeworks BC Inc., Vancouver, BC, Canada
Edward Meier: Zymeworks BC Inc., Vancouver, BC, Canada
Sifa Arrafi: Zymeworks BC Inc., Vancouver, BC, Canada
Anna Von Rossum: Zymeworks BC Inc., Vancouver, BC, Canada
Genevieve Desjardins: Zymeworks BC Inc., Vancouver, BC, Canada
Nina Weisser: Zymeworks BC Inc., Vancouver, BC, Canada
Thomas Spreter von Kreudenstein: Zymeworks BC Inc., Vancouver, BC, Canada

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.1396
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal